Topical corticosteroid-induced adrenocortical insufficiency: Clinical implications

被引:84
作者
Levin C. [1 ]
Maibach H.I. [1 ]
机构
[1] Department of Dermatology, Univ. CA at San Francisco Med. Ctr., San Francisco, CA 94143-0989
关键词
Adrenal Insufficiency; Topical Corticosteroid; Plasma Cortisol Level; Adrenal Suppression; Seborrheic Dermatitis;
D O I
10.2165/00128071-200203030-00001
中图分类号
学科分类号
摘要
Topical corticosteroids are often prescribed for the treatment of dermatological disorders. However, systemic adrenal insufficiency may result from their overuse. Current literature detailing both laboratory and clinical findings was analyzed, in the hopes of evaluating the health-risk potential of topical corticosteroids in producing adrenal insufficiency. Risk factors identified in this report included use of high potency corticosteroids, occlusive or prolonged treatment application, and use in thin-skinned areas. Other patients at risk for development of adrenal suppression include infants and those with damaged skin barriers. Several diagnostic tests may be utilized to measure adrenal function, though each has its limitations. The most common tests include measurement of plasma total cortisol, 24-hour steroid, adrenocorticotrophin hormone stimulation and insulin tolerance. The report finds strong laboratory evidence of adrenal hypofunction. Additionally, clinical reversible adrenal insufficiency has been observed on rare occasions. Therefore, topical corticosteroids should be used with an increased awareness of the potential for systemic adrenal suppressive effects. However, since nonreversible clinical secondary adrenocortical-insufficiency disease has not been clearly documented with even class 1 topical corticosteroids, native adrenal supplementation in periods of stress appears unnecessary; rare exceptions cannot be excluded.
引用
收藏
页码:141 / 147
页数:6
相关论文
共 57 条
[1]  
Plager J., Cushman P., Suppression of the pituitary ACTH response in man by administration of ACTH or cortisol, J Clin Endocrinol Metab, 22, (1962)
[2]  
Loriaux D., Adrenocortical insufficiency, Principles and practice of endocrinology and metabolism, pp. 682-686, (1995)
[3]  
Weston W.L., Fennessey P.V., Morelli J., Et al., Comparison of hypothalamus-pituitary-adrenal axis suppression from superpotent topical steroids by standard endocrine function testing and gas-chromatographic mass-spectrometry, J Invest Dermatol, 90, 4, pp. 532-535, (1988)
[4]  
Katz H.I., Hien N.T., Prawer S.E., Et al., Superpotent topical steroid treatment of psoriasis vulgaris: Clinical efficacy and adrenal function, J Am Acad Dermatol, 16, 4, pp. 804-811, (1987)
[5]  
Garden J.M., Freinkel R.K., Systemic absorption of topical steroids: Metabolic effects as an index of mild hypercortisolism, Arch Dermatol, 122, 9, pp. 1007-1010, (1986)
[6]  
Walsh P., Aeling J.L., Huff L., Et al., Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids, J Am Acad Dermatol, 29, 3, pp. 501-503, (1993)
[7]  
Turpeinen M., Salo O.P., Leisti S., Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease, Br J Dermatol, 115, pp. 475-484, (1986)
[8]  
Turpeinen M., Adrenocortical response to adrenocorticotropic hormone in relation to duration of topical therapy and percutaneous absorption of hydrocortisone in children with dermatitis, Eur J Pediatr, 148, pp. 729-731, (1989)
[9]  
Kecskes A., Jahn P., Matthes H., Et al., Systemic effects of topically applied methylprednisolone aceponate in healthy-volunteers, J Am Acad Dermatol, 28, 5, pp. 789-792, (1993)
[10]  
Cornell R.C., Stoughton R.B., Six-month controlled study of effect of desoximetasone and betamethasone 17-valerate on the pituitary-adrenal axis, Br J Dermatol, 198, pp. 91-95, (1981)